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ABSTRACT
Purpose To report the real- world experience of using 
topical ciclosporin, Ikervis, in the management of ocular 
surface inflammatory diseases (OSIDs).
Methods This was a retrospective study of patients 
treated with Ikervis for OSIDs at the Queen’s Medical 
Centre, Nottingham, between 2016 and 2019. Relevant 
data, including demographics, indications, clinical 
parameters, outcomes and adverse events, were collected 
and analysed for patients who had completed at least 6 
months follow- up. For analytic purpose, clinical outcome 
was categorised as ’successful’ (resolved or stable 
disease), ’active disease’ and ’drug intolerance’.
Results 463 patients were included; mean age was 
51.1±21.6 years, with a 59.0% female predominance. 
Mean follow- up was 14.6±9.2 months. The most 
common diagnosis was dry eye disease (DED; 322, 
69.5%), followed by allergic eye disease (AED; 53, 
11.4%) and ocular mucous membrane pemphigoid/
Steven- Johnson syndrome (OMMP/SJS; 38, 8.2%). 
Successful treatment was achieved in 343 (74.1%) 
patients, with 44 (9.5%) requiring additional treatment 
and 76 (16.4%) reporting drug intolerance. The efficacy 
of Ikervis was highest in DED (264, 82.0%), followed by 
OMMP/SJS (25, 65.8%) and post- keratoplasty (7, 50.0%; 
p<0.001). Logistic regression analysis demonstrated 
age <70 years (p=0.007), AED (p=0.002) and OMMP/
SJS (p=0.001) as significant predictive factors for Ikervis 
intolerance. AED and post- keratoplasty were 8.16 times 
(95% CI, 2.78 to 23.99) and 13.98 times (95% CI, 4.22 
to 46.28), respectively, more likely to require additional 
treatment compared with DED.
Conclusions Ikervis is a useful steroid- sparing topical 
treatment for managing OSIDs in the real- world setting. 
Preparations with improved tolerability are needed to 
benefit a larger number of patients.
INTRODUCTION
Dry eye disease (DED) is the most common disease 
affecting the ocular surface (OS) in the young and 
old, increasing with age, with a female prepon-
derance.1 2 There are various reports on the inci-
dence and prevalence of DED, which is estimated 
to affect 15%–33% of individuals aged over 65 
years but younger individuals are increasingly 
being affected.2–4 DED is traditionally classified as 
aqueous deficient DED (resulting from affection of 
the lacrimal gland) or evaporative DED (primarily 
due to meibomian gland dysfunction), though 
increasingly a considerable overlap between the two 
is being recognised.5 Many factors operate in the 
aetiology and pathophysiology of DED of which 
inflammation was first recognised as an important 
and consistent component in the report published 
following a Delphi approach to treatment recom-
mendations in 20066 and substantiated in subse-
quent reports.7 8
Steroids have been the mainstay in the manage-
ment of most inflammatory conditions, including 
DED, allergic eye disease (AED), chemical eye 
injury, ocular mucous membrane pemphigoid 
(OMMP), Steven- Johnson syndrome (SJS) and 
many others.9 However, over the last two decades, 
non- glucocorticoid immune- modulators, especially 
ciclosporin A (CsA), have gained prominence as 
steroid- sparing topical therapy for DED.10 11 Oil- 
based CsA preparations were in vogue (Optim-
mune 0.2%, licenced for dogs) and used off- label 
in humans since the 1980s. Restasis (0.05% CsA, 
Allergan, California, USA) was approved and 
licenced by the Food and Drug Administration 
(FDA), USA, for treatment of DED in 2002.12 
However the drug was not available in Canada 
and Europe including the UK, and the market 
authorisation application to the European Medi-
cines Agency (EMA) was withdrawn by Allergan in 
2018.13 In 2015 Ikervis, a CsA eye- drop prepara-
tion (1 mg/mL or 0.1%) was approved by the EMA 
for the treatment of severe DED in adults and by 
the National Institute for Health and Care Excel-
lence, UK, for the treatment of severe keratitis of 
DED not responding to treatment with tear substi-
tutes.14 15 In 2018, the same preparation of CsA 
as in Ikervis (recommended once daily for DED) 
was marketed with a different packaging, under 
the name of Verkazia (recommended four times a 
day) after being approved by EMA for treatment of 
severe vernal keratoconjunctivitis (VKC).16
As the only licenced steroid- sparing anti- 
inflammatory agent available for direct treatment at 
the OS, the incentive and clinical pressure to use 
it for other inflammatory conditions was consider-
able, and as often happens in clinical practice, off- 
label use of Ikervis became an option in a variety of 
clinical scenarios where previous oil- based prepa-
rations of CsA were used with some or significant 
benefit.17 18 We report our real- world experience 
with licenced and off- label use of Ikervis in the 
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MATERIALS AND METHODS
A list of patients who received a prescription of Ikervis (topical 
CsA 0.1%) from April 2016 to October 2019 was obtained from 
the hospital pharmacy database. All the charts were retrospec-
tively analysed and patients who had a follow- up of more than 
6 months were included in the study. An Excel spreadsheet was 
created to standardise the data collection, which included the 
demographic profile, diagnosis, clinical parameters, dose and 
duration of Ikervis treatment and clinical outcome. Diagnosis 
was based on clinical examination, characteristic findings and 
biopsy (where applicable). Patients were categorised into DED, 
AED including VKC and atopic keratoconjunctivitis (AKC), 
OMMP, SJS and post- keratoplasty cases. Diagnoses other than 
these were categorised as ‘others’. These patients included non- 
specific chronic conjunctivitis, limbal stem cell deficiency, neuro-
trophic keratopathy, inflammatory keratitis like superior limbic 
keratitis, inflamed pterygium or pseudopterygium, peripheral 
ulcerative keratitis and scleritis/episcleritis. Clinical parameters 
noted included best corrected visual acuity at baseline and final 
follow- up visit or at the time of discontinuing Ikervis, whichever 
was sooner, intraocular pressure, conjunctival findings, corneal 
findings, dry eye parameters like tear- film breakup time and 
Schirmer’s test II values were recorded. A note was made when 
patients presented with burning sensation or ocular discomfort 
affecting compliance. When Ikervis was discontinued by the 
treating physician within a duration of 6 months, owing to the 
side effects or patient intolerance, patients were not excluded 
but were categorised under the intolerant group when evaluating 
the clinical outcome.
Clinical outcome was defined based on clinical parameters 
on follow- up as: (1) resolved: when the signs and symptoms 
subsided completely for at least 1 month with no requirement 
of further Ikervis treatment; (2) stable: when the disease did not 
resolve nor worsened with ongoing Ikervis and the OS (defined 
as the conjunctiva, cornea and lacrimal apparatus) was free from 
visibly detectable inflammation and/or graft rejection (in post- 
keratoplasty cases); (3) active: flare up of condition or active 
inflammation requiring additional treatment such as topical 
steroids and (4) intolerant: when patient on Ikervis experienced 
burning sensation and discomfort necessitating discontinuation 
of the drug. The treatment was considered a ‘success’ if outcome 
1 (resolved) or outcome 2 (stabilised) were achieved.
Statistical analysis
Statistical analysis was performed using SPSS Statistics V.26 
(IBM SPSS Statistics for Windows). Comparison between 
groups was conducted using Pearson’s χ2 or Fisher’s Exact test 
where appropriate for categorical variables, and unpaired t- test 
or Mann- Whiney U test for continuous variables. Normality 
of data distribution was assumed if the skewness and kurtosis 
z-­values­were­between­−1.96­and­+1.96­and­the­Shapiro-­Wilk­
test p value was >0.05. All continuous data were presented 
as mean±SD. Multivariable logistic regression analysis was 
conducted to determine: (1) the likelihood of patients experi-
encing intolerable side effects of Ikervis; and (2) the likelihood 
of patients requiring additional treatment, particularly topical 
steroids, while on Ikervis. For analysis, the diagnosis was catego-
rised into five groups, namely (1) DED, (2) AED, which included 
VKC and AKC, (3) OMMP/SJS, (4) post- keratoplasty and (5) 
others.
P­value­of­≤0.05­was­considered­statistically­significant.­When­
multiple subgroups were analysed, crude Bonferroni- type adjust-
ment was used to keep the overall false positive rate or alpha 




A total of 463 patients were included in this study; the mean age 
was 51.1±21.6 years, with a 59.0% (n=273) female predom-
inance. The mean follow- up duration was 14.6±9.2 months. 
The most common diagnosis was DED (322, 69.5%), followed 
by AED (53, 11.4%) and OMMP/SJS (38, 8.2%; table 1). Of 
all patients, 343 (74.1%) patients were successfully treated with 
Ikervis. Forty- four (9.5%) required additional treatment such as 
topical steroids and 76 (16.4%) discontinued due to intolerance 
to Ikervis. The majority of patients received once a day (286, 
61.8%) Ikervis treatment, followed by twice a day (173, 37.4%) 
and more than twice a day (4, 0.9%). Summary and details of 
Table 1 Summary of the characteristics of patients treated with 





  0–18 34 (7.3)
  >18 to 30 44 (9.5)
  >31 to 50 98 (21.2)
  >51 to 70 152 (32.8)
  >70 135 (29.2)
Gender
  Female 273 (59.0)
  Male 190 (41.0)
Diagnosis
  Dry eye diseases 322 (69.5)
  AED 53 (11.4)
  OMMP 28 (6.0)
  Post- corneal graft 14 (3.0)
  SJS 10 (2.2)
  Others* 36 (7.8)
CDVA, logMAR
  Baseline 0.24±0.45
  Final 0.23±0.47
Clinical outcome†
  Resolved 119 (25.7)
  Stable 224 (48.4)
  Active 44 (9.5)
  Intolerant to Ikervis 76 (16.4)
Treatment frequency
  Once a day 286 (61.8)
  Twice a day 173 (37.4)
  >Twice a day 4 (0.9)
Follow- up duration, months 14.6±9.2
*Included cases of inflammatory keratitis (n=9), non- specific chronic conjunctivitis 
(n=7), scleritis/episcleritis (n=4), limbal stem cell deficiency (n=3), neurotrophic 
keratopathy (n=2), pseudopterygium (n=2), peripheral ulcerative keratitis (n=2), 
superior limbic keratoconjunctivitis (n=2), uveitis (n=2), epithelial ingrowth (n=1), 
conjunctival granuloma (n=1) and giant papillary conjunctivitis (n=1).
†Clinical outcome is defined as: (1) resolved: resolution of disease without further 
need of Ikervis; (2) stable: stable disease with ongoing Ikervis; (3) active: active 
disease requiring additional treatment such as topical steroids and (4) intolerant: 
Ikervis discontinued due to intolerable side effects.
AED, allergic eye disease (which included vernal keratoconjunctivitis and atopic 
keratoconjunctivitis; CDVA, corrected distance visual acuity; OMMP, ocular mucous 
membrane pemphigoid; SJS, Steven- Johnson syndrome.
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dosing according to the different groups are provided in tables 1 
and 2.
There was a significant difference in the clinical outcome, 
tolerability and dosing frequency of Ikervis among the five groups 
of indications (table 2). The efficacy of Ikervis (including both 
‘resolved’ and ‘stable’ group) was shown to be highest in patients 
with DED (264, 82.0%), followed by OMMP/SJS (25, 65.8%), 
post- keratoplasty (7, 50.0%) and AED (20, 37.7%; p<0.001). 
Intolerable side effects of Ikervis were most commonly experi-
enced in patients with AED (22, 41.5%), followed by OMMP/
SJS (11, 28.9%) and DED (37, 11.5%; p<0.001). When the 
group of patients who did not tolerate Ikervis was excluded from 
the analysis, Ikervis was shown to achieve successful control in 
264 (92.6%) cases of DED, 25 (92.6%) cases of OMMP/SJS and 
20 (64.5%) cases of AED, though 7 (50%) cases of the post- 
keratoplasty patients required additional treatment such as 
topical steroids (table 3).
Logistic regression analysis demonstrated that patients who 
were more than 70 years old were significantly less likely to 
experience intolerable side effects of Ikervis as compared with 
other age groups (table 4). When compared with DED, patients 
with AED and OMMP/SJS were 3.81 times (95% CI, 1.79 to 
8.11) and 3.81 times (95% CI, 1.65 to 8.82) more likely to 
experience intolerable side effects of Ikervis, respectively. Ikervis 
treatment frequency did not show any significant influence on 
the drug tolerability (p=0.79).
After excluding 76 patients who experienced intolerable 
side effects of Ikervis, a total of 387 patients were included 
in the analysis of the clinical outcome. When compared with 
DED, logistic regression analysis showed that AED and post- 
keratoplasty patients were 9.18 times (95% CI, 3.01 to 27.94) 
and 9.59 times (95% CI, 2.66 to 34.57), respectively, more likely 
to require additional treatment such as topical steroids (table 5). 
Patients who received twice a day Ikervis treatment were more 
likely to require additional treatment than those who received 
once a day Ikervis treatment (p=0.04).
DISCUSSION
‘Dry eyes’ is both a symptom and a diagnosis. A symptom, 
reflecting the subjective sensation experienced by the patient 
and a diagnosis by virtue of the label assigned to the condition 
based on clinical signs, such as narrow tear meniscus, rapid 
tear film break- up time and punctate OS erosions; with or 
without the support of tests ranging from the Schirmer’s test 
to in vivo confocal microscopy of the corneal epithelium and 
impression cytology of the OS.19–21 The nomenclature is varied 
with ‘DED’ being the most popular but terms such as kerato-
conjunctivitis sicca, xerosis ophthalmia and others are also used 
with the same connotation. Arguably DED is not one condition 
but a common downstream manifestation of a host of local or 
systemic diagnoses. In addition, disruption of the homeostasis 
of the OS induced by ocular surgery could also trigger or exac-
erbate the manifestation of DED, leading to potentially sight- 
threatening complications.22–24 DED related to laser refractive 
surgery, connective tissue diseases, menopause, graft versus host 
Table 2 Summary of clinical outcome of all patients who received Ikervis and the dosing frequency used, categorised into five indications (total 
n=463 patients)
DED AED OMMP/SJS Post- graft Others
P value*
Total n=322 Total n=53 Total n=38 Total n=14 Total n=36
n (%) n (%) n (%) n (%) n (%)
Outcome
  Resolved 98 (30.4) 6 (11.3) 1 (2.6) 1 (7.1) 13 (36.1) <0.001
  Stable 166 (51.6) 14 (26.4) 24 (63.2) 6 (42.9) 14 (38.9) <0.001
  Active 21 (6.5) 11 (20.8) 2 (5.3) 7 (50.0) 3 (8.3) <0.001
  Intolerant 37 (11.5) 22 (41.5) 11 (28.9) 0 (0.0) 6 (16.7) <0.001
Ikervis frequency 0.007†
  Once a day 212 (65.8) 28 (52.8) 21 (55.3) 3 (21.4) 22 (61.1)
  Twice a day 110 (34.2) 23 (43.4) 17 (44.7) 9 (64.3) 13 (36.1)
  >Twice a day 0 1 (1.9) 0 2 (1.43) 1 (2.8)
Treatment duration, months‡ 12.1±6.4 18.7±8.1 10 24 11.5±10.4 0.08
*Comparison was made among the five indications for each clinical outcome.
†χ2 test was performed to compare the difference among the five indications between group 1 (once a day group) and group 2 (twice a day and >twice a day groups).
‡Treatment duration, presented in mean±SD, refers to the duration of Ikervis used to achieve resolution of the disease. ANOVA test was performed to examine the difference 
among DED, AED and others groups.
AED, allergic eye disease (which included vernal and atopic keratoconjunctivitis; DED, dry eye disease; OMMP, ocular mucous membrane pemphigoid; SJS, Steven- Johnson 
syndrome.

















n (%) P value*
Resolved/stable 264 (92.6) 20 (64.5) 25 (92.6) 7 (50.0) 27 (90.0) <0.001
Active 21 (7.4) 11 (35.5) 2 (7.4) 7 (50.0) 3 (10.0)
*Comparison was made among the five indications.
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disease, cicatrising conjunctivitis or old age may have similar 
characteristic symptoms and signs but are clearly not the same 
disease entity. The term ‘dysfunctional tear syndrome’ though 
less popular, is more apt.6
The first global attempt at a unified definition of DED was 
made in 1995 by the National Eye Institute/Industry working 
group on Clinical Trials in Dry Eye.25 This definition did not 
include the term ‘inflammation’. In the years that followed 
evidence appeared in the literature to demonstrate the key role 
played by inflammation in DED and it became recognised as an 
inflammatory disorder,10 11 which was reflected in the publica-
tion by Behrens et al,6 in the international consensus definition 
of DED. The word ‘inflammation’ was incorporated in the defi-
nition of DED, proposed and published by the Dry Eye Work-
shops I and II.5 7 The latter added ‘neurosensory abnormalities’ 
to the definition to emphasise the role played by damage to OS 
innervation, including nerve inflammation, in DED.5
Anti- inflammatory agents were added to the variety of medi-
cations used to treat DED. Steroids were the obvious choice 
but with known complications associated with their long- term 
use. CsA 0.2%, under the name of ‘optimmune’, has been used 
by veterinary colleagues to treat DED in dogs since the early 
1990s.26–28 CsA in varying concentrations, notably Restasis, and 
more recently Cequa (CsA 0.09%, Sun Pharma, Cranbury, NJ, 
USA), in 2018, has also been used to treat a variety of OS inflam-
matory diseases including DED.12 14
CsA is a lipophilic cyclic polypeptide derived from the 
fungus, Hypocladium inflatum gams. Its major immunomodu-
latory activity relates to its effect on calcineurin. Calcineurin, 
a cytosolic protein, is a serine/threonine phosphatase enzyme, 
the activity of which is regulated by calcium/calcium- binding 
messenger protein (calmodulin) and is important in the activation 
of T lymphocytes. Calcineurin, in a calcium dependent manner, 
dephosphorylates nuclear factor(s) of activated T cells (NFAT 
proteins) allowing them to translocate to the nucleus where they 
activate gene expression of cytokines. CsA binds to ubiquitous 
cytosolic proteins called cyclophilins. Cyclophilin–CsA complex 
binds to calcineurin and inhibits calcineurin- mediated dephos-
phorylation thus blocking the nuclear translocation of NFAT 
protein, thus preventing gene expression and transcription of 
several cytokines, in particular interleukin-2, involved in differ-
entiation and survival of T helper cells.29 30
Ikervis is a 0.1% (1 mg/mL), sterile, unpreserved, oil- in- water 
emulsion of CsA. The eye drops also contains the cationic agent, 
cetalkonium chloride (CKC), which increases the resident time 
of the drops on the OS. Its anti- inflammatory effect covers the 
OS and the lacrimal gland. The same preparation, in a different 
presentation format and licensed for use in children (above 4 
years) at a frequency of four times a day to treat VKC, is called 
Verkazia.16 When we started our patients with Ikervis, Verkazia 
was not in the market. We did however treat our patients with 
VKC with Ikervis at a frequency of 2–4 times a day and noticed 
good efficacy but unfortunately comparatively poor tolerability. 
Our results are consistent with the VEKTIS (VErnal Keratocon-
junctiviTIs Study) study that analysed the efficacy of topical CsA 
0.1% in severe VKC. The authors reported successful use of high 
dose CsA (four times a day) in controlling acute symptoms of 
VKC thereby reducing the need of rescue drugs in nearly one- 
third of each high- dose and low- dose group.31 However, it is 
to be noted that the VEKTIS Study analysed only paediatric 
patients with severe VKC. In the current study, we have analysed 
patients with VKC or AED in all age groups.
Twice as many patients with AED had resolved or were 
stable compared with those that needed additional treatment. 
Table 4 Logistic regression analysis for predicting the likelihood 
of patients experiencing intolerable side effect of topical ciclosporin/
Ikervis (total n=463 patients)
Parameters OR (95% CI) P value
Age, years 0.006
  0–18 3.57 (1.03 to 12.43) 0.045
  >18 to 30 7.50 (2.52 to 22.31) <0.001
  >31 to 50 3.30 (1.23 to 8.87) 0.018
  >51 to 70 4.12 (1.69 to 10.04) 0.002
  >70 Reference –
Gender
  Female 0.99 (0.57 to 1.71) 0.97
  Male Reference –
Indications 0.001
  Dry eye disease Reference –
  AED 3.81 (1.79 to 8.11) 0.001
  OMMP/SJS 3.81 (1.65 to 8.82) 0.002
  Post- keratoplasty* – –
  Others 1.34 (0.51 to 3.50) 0.55
Treatment frequency
  Once a day Reference –
  Twice a day 1.08 (0.63 to 1.85) 0.79
  >Twice a day* – –
*No patient experienced intolerable side effect in this group and therefore analysis 
was not possible.
AED, allergic eye disease (which included vernal keratoconjunctivitis and atopic 
keratoconjunctivitis; OMMP, ocular mucous membrane pemphigoid; SJS, Steven- 
Johnson syndrome.
Table 5 Logistic regression analysis for predicting the likelihood of 
patients requiring additional topical steroids while being treated with 
topical ciclosporin/Ikervis (total n=387 patients). Patients who were 
intolerant to the Ikervis were excluded from this analysis
Parameters OR (95% CI) P value
Age, years 0.04
  0–18 0.62 (0.12 to 3.19) 0.56
  >18 to 30 3.02 (0.86 to 10.61) 0.09
  >31 to 50 0.44 (0.13 to 1.55) 0.2
  >51 to 70 1.59 (0.64 to 3.94) 0.32
  >70 Reference –
Gender
  Female 0.78 (0.37 to 1.65) 0.52
  Male Reference –
Indications <0.001
  Dry eye disease Reference –
  AED 9.18 (3.01 to 27.94) <0.001
  OMMP/SJS 0.90 (0.19 to 4.18) 0.89
  Post- keratoplasty 9.59 (2.66 to 34.57) 0.001
  Others 1.27 (0.34 to 4.78) 0.72
Treatment frequency 0.016
  Once a day Reference –
  Twice a day 2.86 (1.39 to 5.90) 0.04
  >Twice a day 3.19 (0.29 to 35.25) 0.34
AED, allergic eye disease (which included vernal keratoconjunctivitis and atopic 
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Unfortunately, the number that were intolerant were as many as 
those who benefitted. If the tolerance of the medication could 
be improved, the data suggest that many more patients of AED 
would benefit. It is not clear why patients in the older age group 
tolerated the drug better than those in the younger age group. It 
could well be due to the difference in pain threshold of these two 
populations of individuals or sensitivity to excipients including 
CKC. A future longitudinal study will address these effects. AED 
patients also had a greater frequency of instillation compared 
with the DED group but so did the OMMP/SJS and ‘others’ 
groups where tolerability was better. Technically speaking, the 
use of Ikervis for treatment of VKC, through the course of this 
study, would be off- label. DED was the only licensed indication 
and also the one that showed the best outcome in that 82% 
of patients had resolved or were stable and maintained on the 
medication. This group also had the best tolerance, with only 
11.5% having to withdraw treatment due to intolerance. Our 
study demonstrated comparable results in DED patients as the 
SANSIKA Study in which 29.2% patients reported pain on 
instillation with 12.3% having moderate to severe pain.32 Since 
the use of CsA 0.1% in DED is established, we used DED as a 
comparator for the other conditions treated.
Other main OS inflammatory conditions where Ikervis was 
used off- label, were OMMP, SJS and ‘others’. As illustrated in 
table 3, if patients who did not tolerate the drug (hence efficacy 
could not be determined) are excluded; more patients benefitted 
relative to those who did not. Overall, it was encouraging to 
see that the majority of patients in these groups benefitted on 
treatment with Ikervis, making it a viable steroid- sparing option 
for controlling inflammation manifest at the OS, negating the 
long- term risks of steroid induced secondary rise in intraocular 
pressure and cataract.33 Use of topical ciclosporin in high risk 
grafts to prevent graft rejection has been described. In 2004, 
the Cornea Society Survey revealed that 48% clinicians used 
topical CsA in high risk keratoplasties.34 The evidence of the 
benefits of topical CsA has been inconsistent.35 Although a few 
studies have described improvements in rejection- free rates and 
graft survival,36–38 majority of the studies have not been able to 
demonstrate any benefit of the use of topical CsA.39–41 Theoret-
ically, Ikervis could be a potentially useful alternative in corneal 
transplant patients who were ‘steroid responders’. Unfortunately, 
this was not borne out in this study as the efficacy in managing 
or controlling rejection was not significant, with half the patients 
requiring additional steroid medication. However, the number 
of patients was too small for a meaningful conclusion to be 
drawn and a further study of this group of patients with Ikervis 
is warranted to determine appropriate frequency and duration 
of instillation, and efficacy. Use of topical CsA has been shown 
to be of benefit in OMMP/SJS cases.42 43 Our study showed that 
patients with OMMP/SJS were almost as likely to require addi-
tional topical steroids as DED patients and were more intolerant 
to Ikervis. Stable OS was achieved in 63.2% cases, however the 
sample size was small and larger studies are required to establish 
the efficacy and tolerance of Ikervis in these patients.
Based on this study of our real- world experience, we would 
recommend that all non- infective chronic OS inflammatory 
diseases be treated with a short course of preservative free 
topical steroid medication and then switch to CsA drops when a 
response is induced. Those that develop a relapse would require 
additional medication with or without the continuation of CsA. 
This approach will also identify initial steroid non- responders 
where CsA alone is unlikely to help and where systemic immu-
nosuppressive agents may be required to induce a remission. In 
this study, overall 74% of patients benefitted and 16% showed 
intolerance across all groups. Improving tolerance of future 
preparations of CsA could improve the overall efficacy.
The natural course of the chronic conditions included in this 
study is characterised by relapses and remissions. When an acute 
episode was treated and resolved sufficient to discharge the 
patient it was taken as the end point. Hence the term ‘resolved’ 
is used as defined in the Methods section and does not equate to 
a cure. The large number of patients, the long mean follow- up 
duration, the real- world experience and the identification of 
the outcomes to be expected in different groups of inflamma-
tory conditions are important strengths of the study. However, 
there are some limitations. As this was a retrospective study, 
it was difficult to capture quantitatively the data for all 463 
patients. The lack of definitive quantitative data related to all 
the parameters of DED and inflammation is a limitation. The 
inherent limitations of a retrospective study, related to use of 
other topical and particularly systemic medications also apply to 
this study though we have analysed and presented concomitant 
use of steroid drops. In modern day clinical practice, cost is an 
important issue and cost benefit analysis is increasingly being 
taken into consideration for approval of drugs funded by the 
public purse. Such an analysis for Ikervis was beyond the scope 
of this study.
As the incidence and prevalence of DED affecting younger 
and older patients is ever increasing, the quest for alternative 
treatments continues. New studies on immunomodulation of OS 
inflammation place emphasis on novel drug delivery or mech-
anisms targeting T- cells. Cequa (CsA 0.09%) is a nanomicellar 
ciclosporin formulation that enables improved drug penetration 
achieving drug concentrations in conjunctival and corneal cells, 
however, symptoms of stinging and pain continue to be reported 
in 22%.44 OTX- CSI is a long- acting, preservative- free ciclo-
sporin intracanalicular hydrogel insert designed to deliver ciclo-
sporin up to 12 weeks while also occluding the lower punctum 
is currently being evaluated in a Phase I/II safety and tolerability 
study. Lifitegrast, an integrin antagonist that blocks the inter-
action of lymphocyte function- associated antigen-1 (LFA-1) / 
intercellular adhesion molecule-1 (ICAM-1)inhibiting T- cell 
activation and release of pro- inflammatory cytokines, is FDA 
approved as 5% ophthalmic solution (Xiidra) for use in DED. 
While this shows some promise, it currently does not have global 
marketing authorisation.45
The immune system is fundamental to the survival of the host 
against environmental onslaughts from a multitude of agents 
both innate and living. It has evolved and adapted through 
evolution into a very complex system that can deal with current 
and potential future antigens. The approaches adopted above 
by targeting a single molecule are probably inadequate. The 
plethora of molecules, the interlinked pathways, the redundancy 
and ability to constantly adapt imply that no single molecule in 
the immune system is indispensable. Targeting a single specific 
key molecule may contain an immune response (inflammation) 
for a varying period of time but unlikely to make a permanent 
impact. Perhaps this is why the results of studies are so vari-
able, often conflicting, with some patients responding, some 
responding for some time and others not at all.
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